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ABSTRACT 
Long-term use of doxorubicin causes cancer resistance due 
to overexpression of P-glycoprotein (P-gp), a protein that plays a 
role in cell drug efflux. The purpose of this study is to determine 
the action of hesperetin in increasing the cytotoxicity of 
doxorubicin on MCF-7 cancer cells resistant to doxorubicin (MCF-
7/DOX) through suppression of P-gp expression. Cytotoxic assay 
of single and combinational treatment of doxorubicin and 
hesperetin were performed by using MTT assay. Apoptosis 
evidence was examined by using double staining with acridine 
orange and ethidium bromide dyes, while Pgp expression was 
determined by using immunocytochemistry. Hesperetin reduced 
cell viability in dose dependent manner. Both MCF-7 ori and 
MCF-7/DOX cells gave different responses to hesperetin with the 
IC50 values of >500μM and 267μM, respectively. Combining 
treatment of hesperetin and doxorubicin to MCF-7/DOX cells at 
the dose of 95μM and 230nM increased apoptosis evidence and 
suppressed P-gp expression. These results suggest that 
hesperetin enhances the anticancer effect of doxorubicin to 
resistance MCF-7 cells through suppression of P-gp expression. 
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INTRODUCTION 
Drug resistance has become one of the 
problems that often arise in the cancer therapy, 
especially breast cancer (Wong, et al., 2006). 
Breast cancer is the top case of cancer 
occurring among women worldwide. In 
Indonesia, the amount of breast cancer patients 
is about 12.10%, the second only to cervical 
cancer (19.18%). The high mortality rate 
indicates that chemotherapy has not overcome 
cancer disease completely. Problems in the 
chemotherapy of breast cancer have become 
more complicated due to the emergence of 
breast cancer resistance to chemotherapeutic 
agents (Wong et al., 2006). Therefore, strategy 
and development of breast cancer treatment 
should be explored. 
Breast cancer cells’ resistance to 
chemotherapeutic agents is caused by various 
factors. But it predominantly occurs due to the 
increase of Akt activity and expression of multi 
drug resistance 1 (MDR1) gene, the gene encoding 
P-glycoprotein after administration of 
doxorubicin, since doxorubicin has the ability 
to induce the expression of MDR1 gene 
(Emami et al., 2005; Li et al., 2005). Another 
study conducted by Bansal et al. (2009) revealed 
that some chemotherapeutic agents also 
showed similar action. Paclitaxel and 
daunorubicin increased P-gp expression in 
various cells in vitro. Elevated P-gp expression 
induced by chemotherapeutic agents is one of 
the causes of the resistance cases to 
chemotherapy. Because of these problems, the 
development of breast cancer chemotherapy is 
directed to the combination of doxorubicin 
with other compounds (co-chemotherapy) that 
increase the effectiveness of doxorubicin. 
One of the proteins that regulate cell 
proliferation and survival is NF-κB (Wang et al., 
2002). NF-κB is a transcription factor playing 
an important role in regulating proliferation and 
survival genes. Many reports suggested that the 
activation of NF-κB have broad implications 
for cancer resistance to chemotherapeutic 
agents. One of the important role of this 
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transcription factor in rising cells resistance is 
by inducing expression of P-glycoprotein (P-
gp), an efflux protein highly expressed and 
localized in cell membranes (Gilmore, 2006). 
The expression of P-gp might be suppressed 
through abrogation of NF-κB signaling 
pathway, e.g. by inhibiting IKK, a protein 
kinase that plays a role in NF-κB activation. 
Some of the flavonoid compounds that are able 
to inhibit protein kinases are citrus flavonoids. 
Hesperetin is an aglycon form of flavonoid, 
commonly found in citrus fruit peel and was 
reported to perform cytotoxic activity on 
several cancer cells (Meiyanto et al., 2012). Our 
previous study on hesperidin, the glycoside 
forms of hesperetin, showed cytotoxic activity 
on MCF-7 cells and performed a synergistic 
effect with doxorubicin (Hermawan et al., 
2009). Another study revealed that hesperetin 
performed inhibitory effects on breast cancer 
resistance protein (BCRP)-expressed K562 
cancer cells (Imai et al., 2004). Therefore, we 
expect that hesperitin may inhibit NF-kB 
activation leading to suppression of P-gp 
expression.  
This study is conducted to examine the 
cytotoxic effect of hesperetin on doxorubicin-
resistant MCF-7 cells (MCF-7/DOX), together 
with its apoptosis evidence and P-gp 
expression. The results of this study are 
expected to be used as a reference for further 
research in order to explore hesperetin as an 
alternative for co-chemotherapeutic agent in 
breast cancer therapy. 
 
MATERIALS AND METHOD 
Sample preparation and cell culture 
Samples used were hesperetin obtained 
from Sigma-Aldrich (Catalog Number H4125-
1G) and doxorubicin (Ebewe). The human 
breast carcinoma cell line MCF-7 orginal (ori) 
was obtained from Cancer Chemoprevention 
Research Center (CCRC), while doxorubicin-
resistant MCF-7 cells (MCF-7/DOX) were 
generated by inducing MCF-7 ori with low 
concentration of doxorubicin that was then 
characterized to over-express Pgp (Putri, et al., 
2012). The cells were then immanently cultured 
in DMEM supplemented with 10% Fetal 
Bovine Serum  (FBS)  (Sigma-Aldrich,  USA) at 
37°C in 5% CO2 atmosphere, 1% penicillin-
streptomycin. Subcultures were obtained after 
treatment with 0.25% trypsin-EDTA (Gibco, 
Canada). 
 
Cell viability assay: 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay 
Exponentially growing cells were seeded 
on 96-well plates at 1×104 cells per well and 
incubated for 24h before the addition of drugs. 
Stock solution of the test compounds was 
initially dissolved in DMSO and further diluted 
with medium. Following a 24h incubation at 
37°C, 5% CO2 and 100μL of various 
concentration of test extracts were added in 
each well in triplicates and cells were then 
incubated for 24h at 37°C. After that, the 
medium was removed and 100μL of MTT 
reagent (1mg/mL) in medium was added to 
each well. The plates were then incubated at 
37°C for 4h. At the end of the incubation 
period, the supernatants were removed and 
100μL 0.01N HCl SDS solution was added to 
each well. After an overnight incubation at 
37°C, the metabolised MTT dissolved product 
was quantified by reading the absorbance at 
595nm using an ELISA reader (Biorad). 
Absorbance data were then calculated in order 
to get the number of viable cells for both 
control and treated cells. To determine cell 
viability, percent viability was calculated as 
[(absorbance of drug-treated cells)-(absorbance 
of medium)/ (absorbance of control 
(untreated) cells- absorbance of medium)] × 
100%. The IC50 values are defined as the drug 
concentrations required to reduce the 
absorbance by 50% of the control.  
 
Apoptosis assay 
MCF-7/DOX cells were grown on glass 
cover slips in tissue culture dishes (Flacon) and 
were allowed to attach for 24h prior to the 
addition of drug. After the cells were incubated 
with the test drug for 24h, the cover slips were 
washed in phosphate-buffered saline and fixed 
in object glass. Treated cells were stained with 
acridine orange and 5μL of ethidium bromide 
and visualized by fluorescence microscope. 
Viable (normal, green nuclei) and apoptotic 
(condensed, red nuclei) cells were then 
examined. 
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Immunocytochemistry 
MCF-7 ori dan MCF-7/DOX breast 
cancer cells were cultured in a 24-well plates 
(Nalge Nunc International, Denmark) at the 
density of 2 × 105 cells per well, incubated for 
24h. The cells were then treated with 0.5 x IC50 
concentrations of hesperetin. After 24h, cells 
were plated in poly-L-lysin slide. Cells were 
fixed with methanol (pro analysis) for 5min, 
permeabilized for 5min in PBS containing 0.2% 
Triton X-100, blocked in 2% BSA for 1h, and 
stained with the monoclonal antibody P-gp 
(1:400) for 1h. They were then washed with 
PBS 3x5min and stained with bionylated 
secondary antibody for 1h. Incubation in HRP-
streptavidin for 10min was then followed by 
addition of DAB (3,3-diaminobenzidine) for 
5min. Cells were then washed with aquadest, 
counter-stained with Harry’s hematoxylin for 
20s, mounted on glass slides. The cells were 
examined by using a confocal microscope.  
 
Data analysis 
The data were analyzed using SPSS 15.0 
software. Oneway Anova were employed to 
assess the statistical significance of difference 
between untreated and different treatment 
group. A statistically significant difference was 
considered to be present at P < 0.05. 
 
RESULTS AND DISCUSSION 
Efect of hesperetin on cell viability of 
MCF-7/DOX 
Inhibitory effect of hesperetin on MCF-
7 ori and MCF-7/DOX cells was evaluated by 
using MTT assay. Exposure of hesperetin at 
various concentrations for 24h showed cell 
growth inhibition in a concentration-dependent 
manner. Hesperetin on MCF-7 ori cells showed 
the cytotoxic effects with IC50 value greater 
than 500μM, whereas the IC50 on MCF-7/DOX 
cells was 267μM (Figure 1). It was an 
interesting finding to be developed, because 
hesperetin was observed to be able to increase 
cell sensitivity on MCF-7/DOX against 
doxorubicin. Hesperetin, in combination with 
doxorubicin on MCF-7/DOX cells showed an 
increase in sensitivity of the cells. Therefore, we 
combined hesperetin and doxorubicin on 
MCF-7/DOX cells. The combination of 
hesperetin and doxorubicin showed increased 
cytotoxic effect, compared with doxorubicin 
 
 
Figure 1. Hesperetin increased sensitivity of MCF/7Dox cells to 
doxorubicin. Cells were seeded in 96-well plates at a density of 
10x103cells per well for 24h, and then treated with various concentrations 
of hesperetin for 24h. Cell viability was then determined by adding MTT 
reagent and measuring the absorbance at 595nm as described in ‘Materials 
and methods’. IC50 was determined from a plot of percent cell viability 
from untreated control cells versus concentration. All results are 
expressed as mean ± SD from three independent experiments 
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alone. At a fixed concentration of doxorubicin, 
higher concentration of hesperetin used 
showed more potent   cytotoxic   effect by the 
combination in cell viability compared with the 
single treatment. The optimum concentration 
was obtained in the combination of 230nM 
doxorubicin and 95μM hesperetin (Figure 2). 
The observation of apoptosis and P-gp 
expression was performed in this 
concentration. 
 
Apoptosis effect of doxorubicin and 
hesperetin on MCF-7/DOX cells 
To observe the effect of hesperetin alone 
and its combination to induce apoptosis on 
MCF-7/DOX cells, observation was conducted 
by using double staining method by using 
acridine orange-ethidium bromide (EB-AO). 
All control cells was in green colour, showing 
no cell death. Single treatment of hesperetin 
and doxorubicin solely resulted in green colour 
of most cells and orange colour of the rest. It 
indicates the loss of membrane permeability as 
an indication of cell death. Cells undergoing 
apoptosis showed an orange fluorescence in the 
cell nucleus fragmentation that became 
apoptotic bodies. Combinational treatment            
of doxorubicin and hesperetin gave more 
orange colour compared with the single 
treatment (Figure 3). This data suggest that the 
increase of effectiveness of doxorubicin’s 
cytotoxicity on MCF-7/DOX cells is mediated 
by the induction of the apoptosis. 
 
Hesperetin and the effects of 
doxorubicin on the expression of P-gp 
To find the molecular mechanism of 
hesperetin in increasing the sensitivity of MCF-
7/DOX, we observed the expression of P-gp 
transporter. P-gp is a protein that is responsible 
for cancer cells’ resistance to doxorubicin. The 
observation on P-gp expression by using 
imunocytochemistry showed excessive 
expression in cancer cells MCF-7/DOX with 
doxorubicin treatment. While the single 
hesperetin treatment showed no significant 
change in expression compared to untreated 
cells (Figure 4).  
In this research, the biological activity of 
hesperetin in overcoming the resistance to 
chemotherapy drug was investigated. MTT 
results showed that hesperetin was able to 
 
 
Figure 2. The effect of hesperetin and doxorubicin to MCF-7/DOX cells’ viability. Cells were 
seeded in 96-well plates at a density of 10x103 cells with hesperetin concentration 15µM (A), 70µM (B) 
and 95µM (C) and doxorubicin (230nM) towards MCF-7/DOX for 24h. After 24h, MTT reagent was 
added to calculate the absorbance which represents viable cells. Cell viability profile was shown from 
average ± standard of error (SE) of 3 experiments. * P < 0.05 
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increase MCF-7/DOX cells’ sensitivity to 
doxorubicin with IC50 values lower than that is 
on MCF-7 cells. Hesperetin in combination 
with doxorubicin is interesting in overcoming 
the resistance, through its action in inducing 
apoptosis and suppressing the expression of P-
gp. 
Hesperetin was able to increase the 
sensitivity of cells with decreasing IC50 
MCF7/DOX to 267μM compared to MCF-7 
(more than 500μM). Increased sensitivity of 
MCF-7/DOX cells by hesperetin was very 
interesting to be explored. These results are 
consistent with several studies that 
polyphenols, such as flavonol quercetin, 
increased the sensitivity of cells that are 
resistant to daunorubicin (Borska et al., 2010). 
Several other flavonoids such as silymarine 
biokanine A and Multiple Drug Resistance were 
able to reverse the function of P-gp inhibition 
(Chung et al., 2005). 
The combination of doxorubicin-
hesperetin on MCF-7/DOX cells showed that 
hesperetin was able to increase the cytotoxic 
effects of doxorubicin. In previous research 
conducted by Hermawan et al., (2010), 
hesperidin (glycoside form of hesperetin) 
showed cytotoxic effects on some cancer cells. 
Greatest cytotoxic effect was obtained at 200 
nM of doxorubicin and 100μM of hesperidin. 
In this study, the combination of hesperetin-
doxorubicin concentration of 95μM and 
230nM showed optimum concentration. This 
data suggest that both hesperitin and hesperidin 
showed a similar profile. 
The combination of hesperetin and 
doxorubicin based on double staining method 
caused cells to form apoptotic bodies, which 
means that hesperetin is possible to increase 
the cytotoxic effects of doxorubicin via 
apoptosis. Combination of the two showed 
increased incidence of apoptosis compared 
 
Figure 3. The apoptotic effect of doxorubicin, hesperetin and combination with doxorubicin on 
MCF-7/DOX cells.  MCF-7/DOX cells were treated by doxorubicin, hesperetin, and their 
combination for 24h and stained by etidium bromide-acridine orange. (A) Untreated cells; (B) cells 
treated with doxorubicin 230nM, (C) hesperetin 95μM, and (D) combination of hesperetin 95μM 
and doxorubicin 200nM. Viable cells give green fluorescence, apoptotic cells give orange 
fluorescence (pointed by red arrow). Examination of apoptosis was done by using fluorescent 
microscope with magnification 400 x. Hesperetin increased apoptosis induction of doxorubicin on 
MCF-7/DOX cells.  
 
 
Figure 4. Effect of Hesperitin on P-gp Expression in MCF-7/DOX cells. MCF-7/DOX cells 
cultured in 24-well plates with density 1 × 105 cells per well on coverslip. (A) Control without 
antibody; (B) control with antibody; (C) cells treated with doxorubicin 230 nM, (D) 95 μM 
hesperetin, and (E) combination doxorubicine 230 nM and hesperetin 95 μM. Pgp expression 
located in cell membrane showed brown color (red arrow). 
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with the single treatment. Increased apoptosis 
also occurs in other citrus flavonoids, such as 
naringenin-doxorubicin combination on T47D 
cells observed by Junedi et al., (2010) and on 
MCF-7 cells observed by Fitriasari et al., (2010). 
These results strengthen the evidence that 
hesperetin is a potential candidate in enhancing 
the cytotoxic effects of doxorubicin through 
the induction of apoptosis. 
Level of doxorubicin at 200nM did not 
cause suppression of Bcl-2 expression in MCF-
7 (Meiyanto et al., 2009). Increased apoptosis 
induction of doxorubicin by hesperetin is likely 
caused by suppression of Bcl-2 and increased 
expression of p53. 100μMm of hesperidin has 
been proven to suppress the expression of Bcl-
2 in colon cancer cells (Park et al., 2008). 
Therefore, it is possible that hesperetin’s ability 
to improve apoptosis induction by doxorubicin 
on MCF-7 cells is mediated by the suppression 
of Bcl-2 expression. Besides, the mechanism of 
apoptosis induction may also occur through the 
increasing expression of p53 as a transcription 
factor that would increase the expression of 
Bax. Li et al., (2007) stated that 200nM 
doxorubicin increased Bax expression in MCF-
7 cells. But this needs further investigation. 
Pharmacological effects of a compound 
affect the molecular changes in cells.         
Increased sensitivity of MCF-7/DOX            
cells to doxorubicin by hesperetin is associated 
with marker proteins. A protein closely           
related to drug resistance is P-glycoprotein.          
P-glycoprotein is a glycoprotein that is 
responsible for drug, carcinogens, toxins, and 
other xenobiotics efflux out of the cell in 
various organs (Bansal et al., 2009). 
Doxorubicin treatment increased the 
expression of P-gp in MCF-7/DOX cells 
significantly compared with the control cells. 
Hesperetin and doxorubicin treatment on 
MCF-7/DOX cells results in a decrease of P-gp 
on the cell membrane compared with the cells 
treated with doxorubicin alone. This 
phenomenon demonstrates the ability of 
hesperetin in modulating P-gp expression. This 
fact is in line with the exploration that some 
flavonoids such as quercetin modulate the 
expression of P-gp and biokanin A (Chung et 
al., 2005). 
The overall results showed that the 
combination of doxorubicin and hesperetin has 
a favorable outlook for breast cancer therapy. 
With hesperetin, the effectiveness of therapy 
can be optimized to increase the sensitivity, 
induce the apoptosis, and suppress P-gp 
expression. Hesperetin can be developed as a 
co-chemotherapy agent for doxorubicin and 
need to be further studied to reveal its 
molecular mechanisms, so that further 
application of the combination of doxorubicin-
hesperetin would be optimum. 
 
CONCLUSIONS 
Hesperetin has cytotoxic effect on MCF-
7/DOX cells with IC50 of 95 µM and increases 
the apoptotic induction when combined with 
doxorubicin. Co-chemotherapy application of 
doxorubicin and hesperetin on MCF-7/DOX 
cells showed synergism effect through 
suppression of P-gp expression. 
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